Two developments advance in vivo gene engineering tools and companies. A Nature Biotechnology paper describes engineered recombinases capable of precise, site‑specific DNA insertion in human cells without reliance on landing pads — a technical step that could simplify stable genomic payload integration. In industry news, Azalea Therapeutics emerged from stealth to commercialize a suite of in vivo cell‑editing technologies developed by Bay Area academics, aiming at therapeutic delivery platforms that edit cells directly in patients. Together the academic advance and new venture point to accelerating translation of safer, more flexible genome‑insertion strategies.